Menu
Marginal structural models (MSM), a type of statistical model, are used to estimate causal links in observational/cohort data and therefore have been used to mimic clinical trials. However, there is an unmet need to broaden the current scope of what can be addressed by MSM, such as long-term effects of interventions, delayed effects of interventions and comparing multiple interventions. Â
The research team have developed this project to extend the present capabilities of MSM to include studies beyond the capabilities of clinical trials. These methods will enable researchers to use real-life data to draw conclusions about long-term and delayed treatment effects and compare multiple therapies. Â
Professor Tomas Kalincik and his team have assembled and quality-checked a dataset from MSBase, an international database consisting of real-world data on people with MS, to allow them to compare seven disease modifying therapies (DMTs) over time. The team have adopted analytical methods and study design features to allow simultaneous analysis of multiple MS therapies over time. Â
Over the next 12 months, Professor Kalincik and his team will work on the dataset, using two complementary methods to compare the effectiveness of treatments.Â
Diouf I, Malpas CB, Sharmin S, et al. Effectiveness of multiple disease modifying therapies in relapsing-remittingmultiple sclerosis: causal inference to emulate a multi-arm randomised trial. J Neurol Neurosurg Psychiatry 2023,94:1004-11Â
Updated: 31 March 2024
Updated: 14 February, 2022
Laboratory research that investigates scientific theories behind the possible causes, disease progression, ways to diagnose and better treat MS.
Research that builds on fundamental scientific research to develop new therapies, medical procedures or diagnostics and advances it closer to the clinic.
Clinical research is the culmination of fundamental and translational research turning those research discoveries into treatments and interventions for people with MS.
$247,924
3 years
